NASDAQ:AMED - Amedisys Stock Price, Forecast & News

Amedisys' stock was trading at $170.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AMED shares have increased by 5.6% and is now trading at $179.95. View which stocks have been mosted impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amedisys.

Amedisys is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Amedisys.

Amedisys Inc (NASDAQ:AMED) announced its earnings results on Tuesday, February, 18th. The health services provider reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.93 by $0.01. The health services provider earned $500.70 million during the quarter, compared to analysts' expectations of $511.58 million. Amedisys had a net margin of 6.49% and a return on equity of 24.95%. The company's revenue for the quarter was up 15.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.91 EPS. View Amedisys' earnings history.

Amedisys updated its FY20 earnings guidance on Tuesday, February, 18th. The company provided EPS guidance of $4.90-5.13 for the period, compared to the Thomson Reuters consensus estimate of $4.91. The company issued revenue guidance of $2.115-2.160 billion, compared to the consensus revenue estimate of $2.12 billion.

13 Wall Street analysts have issued 1 year price objectives for Amedisys' stock. Their forecasts range from $125.00 to $225.00. On average, they anticipate Amedisys' share price to reach $182.86 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price. View analysts' price targets for Amedisys.

News articles about AMED stock have trended negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amedisys earned a news impact score of -2.4 on InfoTrie's scale. They also gave news headlines about the health services provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutAmedisys.

Amedisys saw a increase in short interest in March. As of March 13th, there was short interest totaling 1,117,200 shares, an increase of 6.4% from the February 27th total of 1,050,000 shares. Based on an average trading volume of 292,900 shares, the short-interest ratio is currently 3.8 days. Approximately 3.5% of the company's shares are short sold. View Amedisys' Current Options Chain.

Some companies that are related to Amedisys include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), MEDNAX (MD), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include Alibaba Group (BABA), NVIDIA (NVDA), Cisco Systems (CSCO), CVS Health (CVS), Micron Technology (MU), Netflix (NFLX), Verizon Communications (VZ), QUALCOMM (QCOM), Adobe (ADBE) and Broadcom (AVGO).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by a number of retail and institutional investors. Top institutional investors include William Blair Investment Management LLC (3.32%), State Street Corp (3.12%), Alliancebernstein L.P. (2.17%), Riverbridge Partners LLC (2.06%), Norges Bank (1.69%) and Geode Capital Management LLC (1.46%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Kkr Credit Advisors (Us) Llc, Linda J Hall, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps. View institutional ownership trends for Amedisys.

AMED stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Bank of New York Mellon Corp, AQR Capital Management LLC, FMR LLC, Nuveen Asset Management LLC, Marshall Wace LLP, Rothschild & Co. Asset Management US Inc., and Marshall Wace North America L.P.. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, and Sharon Brunecz. View insider buying and selling activity for Amedisys.

AMED stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Bank of America Corp DE, Castleark Management LLC, William Blair Investment Management LLC, British Airways Pensions Investment Management Ltd, Columbus Circle Investors, Renaissance Technologies LLC, and AXA. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps. View insider buying and selling activity for Amedisys.

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMED stock can currently be purchased for approximately $179.95.

Amedisys has a market capitalization of $5.81 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe. View additional information about Amedisys.

The official website for Amedisys is http://www.amedisys.com/.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]